Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 24, 2012, Pages 9629-9634

  Bulawa, Christine E ^a   Connelly, Stephen ^b   DeVit, Michael ^c   Wang, Lan ^d   Weigel, Charlotte ^a   Fleming, James A ^a   Packman, Jeff ^c   Powers, Evan T ^b   Wiseman, R Luke ^b   Foss, Theodore R ^e   Wilson, Ian A ^b   Kelly, Jeffery W ^b   Labaudinière, Richard ^c  

^a PFIZER INC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c FoldRx Pharmaceuticals Inc   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e Life Technologies   (United States)

Author keywords

Aggregation inhibition; Drug

Indexed keywords

AMYLOID; AMYLOID PROTEIN; PREALBUMIN; TAFAMIDIS; TETRAMER; THYROXINE;

AMYLOIDOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG STABILITY; DRUG STRUCTURE; FIBER; HUMAN; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ANALYSIS; THERMODYNAMICS;

AMYLOID; BENZOXAZOLES; BINDING SITES; HUMANS; KINETICS; MODELS, MOLECULAR; PREALBUMIN;

EID: 84862234023     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1121005109     Document Type: Article

References (60)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356. (Pubitemid 34790756)
2. Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296:1991-1995. (Pubitemid 34627514)
3. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333-366. (Pubitemid 44118036)
4. Benson MD (1989) Familial amyloidotic polyneuropathy. Trends Neurosci 12:88-92.
5. Ando Y, Suhr OB (1998) Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid 5:288-300. (Pubitemid 128690769)
6. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH (2005) Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 165:1425-1429. (Pubitemid 40973426)
7. Westermark P, Sletten K, Johansson B, Cornwell GG, 3rd (1990) Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 87:2843-2845.
8. Saraiva MJM(1995) Transthyretinmutations in health and disease. HumMutat 5:191-196.
9. Jacobson DR, et al. (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336:466-473. (Pubitemid 27074357)
10. Blake CC, Geisow MJ, Oatley SJ, Rérat B, Rérat C (1978) Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol 121:339-356. (Pubitemid 8361803)
11. Monaco HL, Rizzi M, Coda A (1995) Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein. Science 268:1039-1041.
12. Wojtczak A, Cody V, Luft JR, Pangborn W (1996) Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3′,5′-dinitro-N-acetyl-L-thyronine at 2.2 A resolution. Acta Crystallogr D Biol Crystallogr 52:758-765.
13. Hörnberg A, Eneqvist T, Olofsson A, Lundgren E, Sauer-Eriksson AE (2000) A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J Mol Biol 302:649-669.
14. Foss TR, Wiseman RL, Kelly JW (2005) The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 44:15525-15533. (Pubitemid 41706136)
15. Johnson SM, et al. (2005) Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses. Acc Chem Res 38:911-921.
16. Colon W, Kelly JW (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31:8654-8660.
17. Hammarström P, Wiseman RL, Powers ET, Kelly JW (2003) Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299: 713-716. (Pubitemid 36159487)
18. Liu K, Cho HS, Lashuel HA, Kelly JW, Wemmer DE (2000) A glimpse of a possible amyloidogenic intermediate of transthyretin. Nat Struct Biol 7:754-757.
19. Hurshman AR, White JT, Powers ET, Kelly JW (2004) Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 43:7365-7381. (Pubitemid 38745754)
20. Andersson K, Olofsson A, Nielsen EH, Svehag SE, Lundgren E (2002) Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 294:309-314. (Pubitemid 34694094)
21. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN (2004) Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 101:2817-2822. (Pubitemid 38327694)
22. Sousa MM, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: Evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159:1993-2000. (Pubitemid 33104254)
23. Bourgault S, et al. (2011) Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun 410:707-713.
24. Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW (2002) Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 99(Suppl 4):16427-16432. (Pubitemid 35470989)
25. Sekijima Y, et al. (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121:73-85.
26. Jiang X, Buxbaum JN, Kelly JW (2001) The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA 98:14943-14948. (Pubitemid 34013949)
27. Coelho T, et al. (1996) Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscul Disord 6:27.
28. Hammarström P, Schneider F, Kelly JW (2001) Trans-suppression of misfolding in an amyloid disease. Science 293:2459-2462. (Pubitemid 32917328)
29. Longo Alves I, Hays MT, Saraiva MJM (1997) Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur J Biochem 249:662-668. (Pubitemid 27479035)
30. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW (2004) Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 47:355-374. (Pubitemid 38057880)
31. Miller SR, Sekijima Y, Kelly JW (2004) Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84:545-552. (Pubitemid 38858463)
32. Razavi H, et al. (2003) Benzoxazoles as transthyretin amyloid fibril inhibitors: Synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl 42:2758-2761. (Pubitemid 36807218)
33. Wiseman RL, et al. (2005) Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc 127:5540-5551. (Pubitemid 40569865)
34. Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA (2010) Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol 20:54-62.
35. Kolstoe SE, et al. (2010) Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci USA 107:20483-20488.
36. Baures PW, Oza VB, Peterson SA, Kelly JW (1999) Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 7:1339-1347. (Pubitemid 29292374)
37. Baures PW, Peterson SA, Kelly JW (1998) Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem 6:1389-1401. (Pubitemid 28398970)
38. Choi S-W, et al. (2010) A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J Am Chem Soc 132:1359-1370.
39. Green NS, Palaninathan SK, Sacchettini JC, Kelly JW (2003) Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J Am Chem Soc 125:13404-13414. (Pubitemid 37352125)
40. Johnson SM, Connelly S, Wilson IA, Kelly JW (2008) Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem 51:6348-6358.
41. Johnson SM, Connelly S, Wilson IA, Kelly JW (2008) Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem 51:260-270.
42. Klabunde T, et al. (2000) Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 7:312-321. (Pubitemid 30194456)
43. Oza VB, Petrassi HM, Purkey HE, Kelly JW (1999) Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg Med Chem Lett 9: 1-6. (Pubitemid 29023287)
44. Oza VB, et al. (2002) Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem 45:321-332. (Pubitemid 34073451)
45. Petrassi HM, Klabunde T, Sacchettini J, Kelly JW (2000) Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J Am Chem Soc 122: 2178-2192. (Pubitemid 30164628)
46. Hurshman Babbes AR, Powers ET, Kelly JW (2008) Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: The relationship between stability and amyloidosis. Biochemistry 47:6969-6984. (Pubitemid 351898951)
47. Hammarström P, Jiang X, Deechongkit S, Kelly JW (2001) Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: Insight into the chaotrope unfolding dichotomy. Biochemistry 40:11453-11459. (Pubitemid 32911288)
48. Schneider F, Hammarström P, Kelly JW (2001) Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci 10:1606-1613. (Pubitemid 32667054)
49. Wiseman RL, Green NS, Kelly JW (2005) Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: Implications for transthyretin amyloidosis. Biochemistry 44:9265-9274. (Pubitemid 40943241)
50. Wyman J, Gill SJ (1990) Binding and Linkage: Functional Chemistry of Biological Macromolecules (University Science Books, Mill Valley, CA).
51. Purkey HE, Dorrell MI, Kelly JW (2001) Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci USA 98: 5566-5571. (Pubitemid 32435682)
52. Purkey HE, et al. (2004) Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: Rationalizing rodent PCB toxicity. Chem Biol 11:1719-1728. (Pubitemid 39660997)
53. Sekijima Y, Dendle MA, Kelly JW (2006) Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13:236-249. (Pubitemid 44764463)
54. Blirup-Jensen S (2001) Protein standardization III: Method optimization basic principles for quantitative determination of human serum proteins on automated instruments based on turbidimetry or nephelometry. Clin Chem Lab Med 39:1098-1109.
55. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT, Jr. (2002) Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature 418:291. (Pubitemid 34790672)
56. Bartalena L, Robbins J (1993) Thyroid hormone transport proteins. Clin Lab Med 13: 583-598. (Pubitemid 23267628)
57. Rosen HN, Moses AC, Murrell JR, Liepnieks JJ, Benson MD (1993) Thyroxine interactions with transthyretin: A comparison of 10 different naturally occurring human transthyretin variants. J Clin Endocrinol Metab 77:370-374. (Pubitemid 23230042)
58. Holmgren G, et al. (1992) Homozygosity for the transthyretin-Met30-gene in seven individuals with familial amyloidosis with polyneuropathy detected by restriction enzyme analysis of amplified genomic DNA sequences. Clin Genet 41:39-41.
59. Coelho T, et al. (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology, in press.
60. Cody V, Wojtczak A (2009) Mechanisms of molecular recognition:structural characteristics of transthyretin ligand interactions. Recent Advances in Transthyretin Evolution, Structure and Biological Functions, eds Richardson SJ and Cody V (Springer, Berlin), pp 1-21.